Position in NTLA
as of Jun 30, 2026
· filed Jul 10, 2026
Position Value
$2,159,821
-$1,197,275 QoQ
Shares Held
127,649
-51.3% QoQ
Ownership
0.091%
of shares outstanding
% of Portfolio
0.01%
of 13F equity value
Holder Rank
#85
of 330 holders
Holding Since
Dec 2025
3 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in NTLA Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026WASATCH ADVISORS LP holds $96,311,805 across 9 Biotechnology names. NTLA ranks #9 (2.2% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | TARS |
Tarsus Pharmaceuticals, Inc.
|
368,568 | $23,197,669 | |
| 2 | CCCC |
C4 Therapeutics, Inc.
|
3,522,644 | $16,450,747 | |
| 3 | PHAT |
Phathom Pharmaceuticals, Inc.
|
1,307,247 | $14,183,629 | |
| 4 | VKTX |
Viking Therapeutics, Inc.
|
312,767 | $12,201,040 | |
| 5 | DYN |
Dyne Therapeutics, Inc.
|
443,668 | $9,853,866 | |
| 6 | MGNX |
Macrogenics Inc
|
2,018,881 | $9,327,230 | |
| 7 | IMTX |
Immatics N.V.
|
441,510 | $4,472,496 | |
| 8 | NKTX |
Nkarta, Inc.
|
1,577,847 | $4,465,307 |
All Filings in NTLA
Export CSV
3 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $2,159,821 | 127,649 | Shares | Sole | 2026-07-10 | |
| 2026-03-31 | $3,357,096 | 261,864 | Shares | Sole | 2026-04-21 | |
| 2025-12-31 | $2,820,028 | 313,685 | Shares | Sole | 2026-02-12 | |
| No filing history on record for this holder in this stock. | ||||||